Mizuho stays Outperform on Axsome Therapeutics (AXSM) as Auvelity Rx growth accelerates

March 20, 2026 11:06 AM

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $230.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found